This vaccine has been on the market for 8 years.
The nine-valent HPV vaccine was launched in the United States in 2014. Subsequently, on April 28, 2018, the State Food and Drug Administration conditionally approved the nine-valent HPV vaccine for the prevention of cervical cancer to be launched in China.
The nine-valent HPV vaccine is one of the human papillomavirus vaccines. The so-called nine-valent vaccine means that it can prevent cervical cancer caused by infection with nine HPV genotypes. The cancer prevention rate is as high as 90%. %above.